The high free energy and low density of the amorphous phase mean that amorphous pharmaceutical compounds typically dissolve faster than their crystalline forms. However, the metastable nature and propensity to crystallise during formulation and storage are serious concerns for drug developers. Faster dissolution is associated with greater bioavailability and, hence, amorphous drug formulations provide intriguing possibilities in the pharmaceutical industry. The understanding of these systems is complicated due to the significant positional and orientational disorder of the molecules and the lack of long-range periodicity.
